DiFi Xenograft Model Service for Colon Cancer

The DiFi Xenograft Model Service for Colon Cancer offers a robust, preclinical platform for evaluating therapeutic efficacy against colorectal malignancies using the well-characterized DiFi cell line. Alfa Cytology leverages decades of expertise in tumor model development to deliver standardized, high-quality xenograft studies tailored to your drug discovery pipeline, ensuring reproducible data and accelerated decision-making.

Overview of DiFi Xenograft Model for Colon Cancer

The DiFi cell line was originally established from a rectal carcinoma specimen obtained from a patient with familial adenomatous polyposis (FAP) and extracolonic features characteristic of Gardner syndrome. This epithelial cell line retains key phenotypic features of colonic epithelium, including surface microvilli, secretory vesicles, and desmosomes, and has been propagated for over 150 passages in standard culture conditions without feeder layers. DiFi cells exhibit a tetraploid karyotype with numerous marker chromosomes and episomal particles, accompanied by allelic losses on chromosomes 17p and 18 --- genetic alterations frequently observed in colorectal cancer progression. The cell line expresses high levels of the mucin marker CA 19-9 (502 U/mg protein) and produces carcinoembryonic antigen (CEA), making it a valuable tool for studying biomarker dynamics in tumor models.

In xenograft settings, DiFi cells demonstrate reliable tumorigenicity in athymic mice, forming tumors that recapitulate essential histological and molecular characteristics of the parental cell line. The model has been extensively utilized to investigate EGFR-targeted therapy responses, cetuximab resistance mechanisms, and the emergence of KRAS mutations during anti-EGFR treatment. Researchers have leveraged DiFi xenografts to explore the role of transforming growth factor-beta (TGF-beta) in suppressing c-myc expression and inhibiting anchorage-independent growth, providing insights into signaling pathways relevant to colorectal cancer therapeutics.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colorectal cancer progression through APC and TP53 mutations, and how treatments intersect with EGFR-targeted therapy resistance mechanisms.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for CA 19-9 and CEA dynamics.

Figure 1. Evaluation of cell viability by MTT test after NEU3 overexpression and cetuximab administration. (Bovio, F, et al., 2020)

Cell Line Information: DiFi

The DiFi cell line represents a well-documented model system derived from hereditary colorectal cancer, offering unique genetic and phenotypic features for preclinical investigations. Its tetraploid karyotype, APC mutations, and EGFR amplification make it unique among available colon cancer cell lines and essential for preclinical research targeting hereditary colorectal carcinoma and EGFR resistance mechanisms.

Our Services

Alfa Cytology provides comprehensive DiFi Xenograft Model Services for Colon Cancer, encompassing cell line authentication, tumor inoculation, in-life monitoring, endpoint analysis, and histopathological evaluation. Our preclinical platform is designed to support your oncology drug development programs with rigorous quality control, standardized protocols, and flexible study designs that align with your specific research objectives.

Workflow of DiFi Xenograft Model Construction

The construction of a DiFi xenograft model follows a systematic, multi-step workflow designed to ensure tumor engraftment fidelity, reproducibility, and translational relevance. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Preparation and Authentication: DiFi cells are expanded under standard culture conditions and authenticated via STR profiling and mycoplasma testing to confirm identity and purity prior to inoculation.
2. Recipient Mouse Selection and Preparation: Immunodeficient mice (typically athymic nude or NOD/SCID strains) are acclimatized and health-screened to ensure optimal engraftment conditions and minimize host-related variability.
3. Tumor Cell Inoculation: DiFi cells are harvested at logarithmic growth phase, resuspended in a serum-free medium/Matrigel mixture, and subcutaneously or orthotopically injected into the recipient mice at predetermined cell densities.
4. In-Life Monitoring and Tumor Measurement: Mice are monitored daily for health status, and tumor dimensions are measured twice weekly using calipers; body weight and clinical signs are recorded to assess treatment tolerability.
5. Study Endpoint and Sample Collection: Upon reaching predetermined endpoint criteria (tumor volume ~1,500 mm^3 or study duration limit), mice are euthanized, and tumors are excised, weighed, and processed for downstream analyses.
6. Histopathological and Molecular Validation: Excised tumors undergo H&E staining, immunohistochemistry for key biomarkers (e.g., CA 19-9, CEA, EGFR), and molecular profiling to confirm fidelity to the parental DiFi cell line characteristics.

Figure 2: Schematic workflow illustrating the derivation and construction of the DiFi Xenograft Model at Alfa Cytology.

Case Study-DiFi Xenograft Model Development

Alfa Cytology has successfully established and validated the DiFi xenograft model as part of our colon cancer preclinical service portfolio. In a representative study, DiFi cells were engrafted into immunodeficient mice with a high take rate, and tumors demonstrated consistent growth kinetics suitable for therapeutic intervention studies. Treatment arms evaluated candidate compounds against vehicle controls, with tumor growth inhibition, biomarker modulation, and histopathological endpoints assessed to generate comprehensive efficacy profiles. Detailed study data, including tumor growth curves, pharmacodynamic readouts, and survival analyses, are available upon request under confidentiality agreements. Please contact our scientific team to discuss specific data packages and customized study designs tailored to your program needs.

Why Choose Alfa Cytology?

Alfa Cytology stands out as a trusted partner for DiFi Xenograft Model Services, combining scientific rigor with operational flexibility to advance your colon cancer drug development programs.

• Verified Cell Line Integrity: Extensive experience in colorectal cancer xenograft model development with validated DiFi cell line authentication and quality control protocols.
• High Take Rates and Consistency: Customizable study designs accommodating subcutaneous, orthotopic, and metastatic model configurations to match your therapeutic hypothesis.
• Comprehensive Analytical Support: Comprehensive in-life monitoring capabilities including tumor caliper measurements, body weight tracking, and clinical observation by trained veterinary staff.
• Tailored Study Designs: Integrated endpoint analysis encompassing histopathology, immunohistochemistry, biomarker quantification, and molecular profiling within a single service platform.
• Standardized Protocols: Strict adherence to animal welfare guidelines and regulatory standards, ensuring ethical conduct and data integrity across all preclinical studies.
• Dedicated Project Management: Rapid project turnaround with dedicated project management and transparent communication to keep your drug development timeline on track.

Contact Us

Ready to advance your colon cancer preclinical program with the DiFi Xenograft Model? Reach out to us today to discuss your study requirements, obtain a customized proposal, or schedule a consultation with our scientific team. Please reach out to us today via our inquiry form or email to learn more about our DiFi Xenograft Model services.

For research use only. Not intended for any clinical use.